WinstonWınston
Back
Stock

Intellia Therapeutics

NTLA
37
Biotechnology · Healthcare
Also trades as: 0JBU.L GBP 0.11 (-1.34%)
Price
$11.21
+0.05 (+0.45%)
Market Cap
$1.57B
Exchange
NASDAQ
Winston Score
37
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Oct 23, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
10/30
Growth
Strong
14/20
Cash Flow
Weak
0/10
Stability
Good
5/10
Valuation
Data not available
0/10
Ownership
Mixed
6/15
Dividends
Not counted
n/a

35 of 95 counted points = Winston Score 37. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+52.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 70.9M (2021) → 108.4M (2025)

§Winston Score History

The full picture

Intellia Therapeutics is a biotechnology company that uses a gene-editing technology called CRISPR to try to cure diseases by fixing or changing DNA inside a patient's body. Its main focus is on rare diseases caused by genetic mutations, such as transthyretin amyloidosis (a condition where a misfolded protein damages the heart and nerves) and hereditary angioedema. The company's goal is to develop one-time treatments that could permanently correct the underlying genetic cause of a disease, rather than managing symptoms with ongoing medication.

Intellia earns revenue primarily through collaboration agreements with larger pharmaceutical companies — most notably Regeneron — rather than from selling approved drugs, since its treatments are still in clinical trials. It operates mainly in the United States and is a clinical-stage company, meaning it spends far more money than it earns, as reflected in its deeply negative margins. The key risk is that its pipeline candidates must still prove safe and effective in late-stage trials before any product can reach the market and generate meaningful revenue.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-46.2% YoY

YoY Growth Rate

Revenue declining

Reported EPS Growth

+18.4% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.98

30 Jun 2026: $-0.80

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$389M/ year

↓ Declining (-17% vs prior year)

574.6% of revenue

31.9x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

4.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~17 months

$475M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

Revenue declining

Intellia Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
100.0%
Premium pricing power — 100.0% gross margin
Profit after running costs
Operating Margin
-1472.3%
Losing money on operations — -1472.3%
Return on the money invested
ROCE
-52.9%
Weak — -52.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+12.6%
Fast-growing sales (+12.6% YoY)
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
—
Data not available
Spare cash per sale
FCF Margin
-586.0%
Burning cash (-586.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.10
Conservative — low debt load (0.10)
Covers its interest
Interest Cover
N/A
—
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
—
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial